BR0215216A - Composição aquosa lìquida, método para preparar uma composição aquosa lìquida de um polipeptìdeo de fator vii, uso de uma composição aquosa lìquida, e, método para o tratamento de uma sìndrome de resposta ao fator vii - Google Patents

Composição aquosa lìquida, método para preparar uma composição aquosa lìquida de um polipeptìdeo de fator vii, uso de uma composição aquosa lìquida, e, método para o tratamento de uma sìndrome de resposta ao fator vii

Info

Publication number
BR0215216A
BR0215216A BR0215216-9A BR0215216A BR0215216A BR 0215216 A BR0215216 A BR 0215216A BR 0215216 A BR0215216 A BR 0215216A BR 0215216 A BR0215216 A BR 0215216A
Authority
BR
Brazil
Prior art keywords
aqueous composition
liquid aqueous
factor vii
treating
preparing
Prior art date
Application number
BR0215216-9A
Other languages
English (en)
Inventor
Birthe Lykkegaard Hansen
Michael Bech Jensen
Troels Kornfelt
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Publication of BR0215216A publication Critical patent/BR0215216A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"COMPOSIçãO AQUOSA LìQUIDA, MéTODO PARA PREPARAR UMA COMPOSIçãO AQUOSA LìQUIDA DE UM POLIPEPTìDEO DE FATOR VII, USO DE UMA COMPOSIçãO AQUOSA LìQUIDA, E, MéTODO PARA O TRATAMENTO DE UMA SìNDROME DE RESPOSTA AO FATOR VII". Uma composição aquosa líquida compreendendo (i) um polipeptídeo de fator VII, (ii) um agente adequado para manter o pH na faixa de cerca de 4,0 a cerca de 8,0; (iii) um agente escolhido da lista de: um sal de cálcio, um sal de magnésio, ou uma mistura dos mesmos; onde a concentração de (iii) é pelo menos 15 mM.
BR0215216-9A 2001-12-21 2002-12-20 Composição aquosa lìquida, método para preparar uma composição aquosa lìquida de um polipeptìdeo de fator vii, uso de uma composição aquosa lìquida, e, método para o tratamento de uma sìndrome de resposta ao fator vii BR0215216A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200101948 2001-12-21
US34688802P 2002-01-07 2002-01-07
PCT/DK2002/000895 WO2003055512A1 (en) 2001-12-21 2002-12-20 Liquid composition of factor vii polypeptides

Publications (1)

Publication Number Publication Date
BR0215216A true BR0215216A (pt) 2004-11-16

Family

ID=26069118

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0215216-9A BR0215216A (pt) 2001-12-21 2002-12-20 Composição aquosa lìquida, método para preparar uma composição aquosa lìquida de um polipeptìdeo de fator vii, uso de uma composição aquosa lìquida, e, método para o tratamento de uma sìndrome de resposta ao fator vii

Country Status (15)

Country Link
US (2) US8022031B2 (pt)
EP (1) EP1458408B1 (pt)
JP (1) JP2005530683A (pt)
CN (1) CN1607958A (pt)
AT (1) ATE428439T1 (pt)
AU (1) AU2002351756A1 (pt)
BR (1) BR0215216A (pt)
CA (1) CA2470511C (pt)
DE (1) DE60232017D1 (pt)
ES (1) ES2325653T3 (pt)
HU (1) HUP0402315A3 (pt)
IL (1) IL162239A0 (pt)
PL (1) PL370652A1 (pt)
RU (1) RU2357751C2 (pt)
WO (1) WO2003055512A1 (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
ES2325653T3 (es) 2001-12-21 2009-09-11 Novo Nordisk Health Care Ag Composicion liquida de polipeptidos del factor vii.
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
DE60334983D1 (de) 2002-04-30 2010-12-30 Bayer Healthcare Llc Faktor vii oder faktor viia polypeptidvarianten
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
PT1517698E (pt) * 2002-06-21 2014-11-19 Novo Nordisk Healthcare Ag Composições sólidas estabilizadas de polipéptidos do fator viia
EP1549677B1 (en) 2002-09-30 2011-04-13 Bayer HealthCare LLC FVII OR FVIIa VARIANTS HAVING INCREASED CLOTTING ACTIVITY
WO2004082708A2 (en) * 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
WO2004083361A2 (en) 2003-03-20 2004-09-30 Maxygen Holdings Ltd. FVII OR FVIIa VARIANTS
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
MXPA05012476A (es) 2003-05-23 2006-02-22 Novo Nordisk Healthcare Ag Estabilizacion de proteina en solucion.
EP1644504B8 (en) 2003-06-19 2010-06-02 Bayer HealthCare LLC Factor vii or viia gla domain variants
EP1641487B1 (en) 2003-06-25 2012-02-29 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
ES2335994T3 (es) * 2003-07-01 2010-04-07 Novo Nordisk Health Care Ag Composicion farmaceutica liquida, acuosa de polipeptidos factor vii.
ES2574581T3 (es) 2003-08-14 2016-06-20 Novo Nordisk Health Care Ag Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII
WO2005023308A1 (en) * 2003-09-05 2005-03-17 Maxygen Holdings Ltd. Formulations of vitamin k-dependent polypeptides and sulfoalkyl ether cycloextrins
CA2549593C (en) * 2003-12-19 2014-02-11 Novo Nordisk Health Care Ag Stabilised compositions of factor vii polypeptides
PT2708225T (pt) 2004-04-23 2019-05-21 Cydex Pharmaceuticals Inc Formulação de dpi contendo éter sulfoalquílicociclodextrina
RU2006138181A (ru) 2004-05-04 2008-06-10 Ново Нордиск Хелс Кеа Аг (Ch) О-связанные гликоформы полипептидов и способ их изготовления
US7148067B2 (en) * 2004-08-31 2006-12-12 The Board Of Trustees Of The University Of Illinois Thromboplastin reagents
JP2006137678A (ja) * 2004-11-10 2006-06-01 Shionogi & Co Ltd インターロイキン−２組成物
EP1853926A2 (en) * 2005-02-16 2007-11-14 The Board Of Trustees Of The University Of Illinois Procoagulants based on metal-chelating lipids
JP2008531692A (ja) * 2005-03-04 2008-08-14 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 凝固及び線維素溶解カスケードのモジュレーター
AU2012213951B2 (en) * 2005-04-28 2014-10-16 Novo Nordisk Health Care Ag A closed container comprising an activated factor VII polypeptide, processes for the preparation of the same, and a kit and a method for use of the kit
CN101184474B (zh) * 2005-04-28 2013-05-29 诺和诺德医疗保健公司 含有活化的凝血因子ⅶ多肽的密封容器，制备这种容器的方法，和试剂盒以及该试剂盒的使用方法
WO2007003936A1 (en) * 2005-07-02 2007-01-11 Arecor Limited Stable aqueous systems comprising proteins
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
AU2006330858A1 (en) 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof
US9675696B2 (en) * 2006-11-14 2017-06-13 Warsaw Orthopedic, Inc. Method and use for increasing efficacy of anti-adhesive compositions in controlling inflammation and pain
JP2010525034A (ja) * 2007-05-02 2010-07-22 ノボ ノルディスク ヘルス ケア アーゲー 芳香族保存料及び抗酸化剤を含有してなる高濃縮第ｖｉｉ因子ポリペプチド製剤
EP2201111B1 (en) 2007-08-24 2014-08-13 Novo Nordisk Health Care AG Reduction of dimer content in factor vii polypeptide compositions by heat treatment
WO2009046194A2 (en) 2007-10-05 2009-04-09 The Board Of Trustees Of The University Of Illinois Fibrin sealant
US20100297257A1 (en) 2007-11-09 2010-11-25 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs) Anticoagulant antagonist and hemophillia procoagulant
RU2524423C2 (ru) 2008-01-09 2014-07-27 Санофи-Авентис Дойчланд Гмбх Новые производные инсулина с чрезвычайно замедленным профилем время/действие
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
CN102065899A (zh) * 2008-05-23 2011-05-18 诺沃-诺迪斯克保健股份有限公司 含有高浓度的芳香族防腐剂的peg-官能化的丝氨酸蛋白酶的制剂
US20110112029A1 (en) * 2008-05-23 2011-05-12 Novo Nordisk Health Care Ag Low viscosity compositions comprising a pegylated gla-domain containing protein
LT2349324T (lt) 2008-10-17 2017-12-27 Sanofi-Aventis Deutschland Gmbh Insulino ir glp-1 agonisto derinys
MY159865A (en) * 2009-07-06 2017-02-15 Sanofi Aventis Deutschland Aqueous insulin preparations containing methionine
CN102711804B (zh) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 包含glp-1激动剂和甲硫氨酸的药物组合物
CA2780460C (en) 2009-11-13 2018-09-04 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
AU2011223805B2 (en) * 2010-03-01 2015-10-29 Cytodyn Inc. Concentrated protein formulations and uses thereof
RU2546520C2 (ru) 2010-08-30 2015-04-10 Санофи-Авентис Дойчланд Гмбх Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
US9087234B2 (en) * 2013-03-15 2015-07-21 Nike, Inc. Monitoring fitness using a mobile device
EA028016B1 (ru) * 2013-06-06 2017-09-29 Общество с ограниченной ответственностью "Гематологическая Корпорация" (ООО "ГемаКор") Набор для измерения параметров системы гемостаза в образце крови или ее компонентов
HUE062573T2 (hu) 2014-12-12 2023-11-28 Sanofi Aventis Deutschland Glargin inzulin/lixiszenatid rögzített arányú készítmény
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN108476575B (zh) 2015-10-30 2021-02-02 路创技术有限责任公司 调试负载控制系统
WO2019209260A1 (en) * 2018-04-24 2019-10-31 W. L. Gore & Associates, Inc. Medical delivery devices with inhibited oxygen permeation
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US115590A (en) 1871-06-06 Lfxlproxeixie
US2145869A (en) * 1935-07-13 1939-02-07 Garcia Donato Perez Intravenous therapy for the treatment of syphilis
DE2916711A1 (de) 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4956386A (en) 1980-04-25 1990-09-11 Gist-Brocades N.V. Pharmaceutical compositions and process for their preparation
US4404132A (en) 1980-05-27 1983-09-13 Cutter Laboratories, Inc. Blood coagulation promoting product
CA1182748A (en) 1980-11-21 1985-02-19 Gerard Marx Method for synthesizing procoagulant factor viii activity
US4495278A (en) 1981-04-27 1985-01-22 Baxter Travenol Laboratories, Inc. Process for making novel blood clotting enzyme compositions
US4382083A (en) 1981-06-25 1983-05-03 Baxter Travenol Laboratories, Inc. Therapeutic method for treating blood-clotting defects with factor VIIa
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5180583A (en) 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
CA1281647C (en) * 1985-11-26 1991-03-19 Novo Nordisk A/S Compositions and methods for the treatment of bleeding disorders
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
JP2593500B2 (ja) 1986-06-24 1997-03-26 ノルデイスク ゲントフテ エー／エス ▲ｖｉｉｉ▼因子フラグメントの凝固活性複合物の製造方法
DE3877529T2 (de) 1987-10-23 1996-11-07 Centre Regional De Transfusion Herstellung von hoch-gereingtem menschlichen Faktor IX sowie anderem Plasmaproteinkonzentrat und dessen therapeutische Verwendung.
CA1329760C (en) 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US5472850A (en) 1991-04-10 1995-12-05 Oklahoma Medical Research Foundation Quantitative clotting assay for activated factor VII
JP2824430B2 (ja) 1989-08-02 1998-11-11 財団法人化学及血清療法研究所 血液凝固第▲ｖｉｉ▼因子または活性型血液凝固第▲ｖｉｉ▼因子の調製方法
DE3939346A1 (de) 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
DE4001451A1 (de) 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
WO1991011514A1 (en) 1990-01-29 1991-08-08 Zymogenetics, Inc. Anticoagulant proteins
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
CA2103546C (en) 1991-02-28 2002-10-01 Kathleen L. Berkner Modified factor vii
US5817788A (en) 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
WO1993000807A1 (en) 1991-07-03 1993-01-21 Cryolife, Inc. Method for stabilization of biomaterials
FR2684999A1 (fr) 1991-12-16 1993-06-18 Aquitaine Dev Transf Sanguine Procede de fabrication d'un concentre de facteur vii active de haute purete essentiellement depourvu des facteurs vitamine k dependants et des facteurs viiic et viiicag.
JP3155797B2 (ja) 1991-12-26 2001-04-16 株式会社日立製作所 過電圧自己保護型半導体装置、及び、それを使用した半導体回路
AU670793B2 (en) 1992-04-30 1996-08-01 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor VIII complex
WO1994005692A1 (en) 1992-08-27 1994-03-17 Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Nederlandse Rode Kruis Antibodies specific for a haemostatic protein, their use for isolating intact protein, haemostatic compositions devoid of proteolytic cleavage products of the protein
DK38293D0 (da) 1993-03-31 1993-03-31 Novo Nordisk As Fremstilling af proteiner
SE9301581D0 (sv) 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
ES2169074T3 (es) 1993-05-21 2002-07-01 Novo Nordisk Healthcare Ag Factor vii modificado para inhibir la reestenosis vascular o el deposito de plaquetas.
AU7254894A (en) 1993-07-23 1995-02-20 Baxter International Inc. Activated human factor viii and method of preparation
US6277828B1 (en) 1993-08-20 2001-08-21 Syntex (U.S.A.) Inc. Pharmaceutical formulations of nerve growth factor
US5576291A (en) 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
IL113010A (en) 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
DE4435520A1 (de) 1994-10-04 1996-04-11 Immuno Ag Verfahren zur Trennung von rekombinantem pro-Faktor IX von rekombinantem Faktor IX
SE9403915D0 (sv) 1994-11-14 1994-11-14 Annelie Almstedt Process A
US5649959A (en) * 1995-02-10 1997-07-22 Sherwood Medical Company Assembly for sealing a puncture in a vessel
US6255091B1 (en) 1995-04-28 2001-07-03 Axys Pharmaceuticals, Inc. Potentiating metal mediated serine protease inhibitors with cobalt or zinc ions
DE19531637A1 (de) 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
DE19538715A1 (de) 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
SE9503679D0 (sv) 1995-10-20 1995-10-20 Pharmacia Ab Antioxidants
US5993795A (en) * 1995-11-09 1999-11-30 Takemoto Yushi Kabushiki Kaisha Protein composition derived from sesame seed and use thereof
US6320029B1 (en) 1996-11-29 2001-11-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US5925738A (en) 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US5830852A (en) * 1995-12-19 1998-11-03 Cobra Therapeutics, Ltd. Compositions for insulin-receptor mediated nucleic acid delivery
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
DE19903693A1 (de) 1998-04-24 1999-10-28 Centeon Pharma Gmbh Protease zur Aktivierung des Gerinnungsfaktors VII
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
AT403989B (de) 1996-09-16 1998-07-27 Immuno Ag Verfahren zur herstellung eines plasmaprotein-hältigen arzneimittels
US6315995B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
BR9714434A (pt) 1996-12-24 2000-05-02 Biogen Inc Formulações de interferon liquidas estáveis
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
AR015598A1 (es) 1997-04-28 2001-05-16 Lilly Co Eli FORMULACIoN LIOFILIZADA QUE COMPRENDE PROTEíNA C ACTIVADA, SU USO PARA LA PREPARACIoN DE UN MEDICAMENTO Y FORMA DE DOSIS UNITARIA QUE LA COMPRENDE.
DE19730023A1 (de) 1997-07-11 1999-01-14 Bayer Ag Hochreine Ciprofloxacin-Infusion
US6461610B1 (en) 1997-07-18 2002-10-08 Novo Nordisk A/S Methods for modifying cell motility using factor VIIa or inactivated factor VIIa
US6310183B1 (en) 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
AT409334B (de) 1997-09-19 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren
AT408613B (de) 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
CA2342606A1 (en) 1998-10-07 2000-04-13 Sigma-Aldrich Co. Thromboplastin reagents and methods for preparing and using such reagents
DE19853033A1 (de) 1998-11-18 2000-05-25 Centeon Pharma Gmbh Stabilisierte Proteinzubereitung für einen Gewebekleber
CA2362927C (en) 1999-02-22 2011-07-12 University Of Connecticut Novel albumin-free factor viii formulations
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
US20010031721A1 (en) * 1999-05-05 2001-10-18 Chandra Webb Highly concentrated, lyophilized, and liquid factor IX formulations
ATE310533T1 (de) 1999-07-13 2005-12-15 Zusammensetzungen mit stabilem faktor viii
DE19937218A1 (de) 1999-08-06 2001-02-08 Aventis Behring Gmbh Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Affinitätschromatographie
US6586574B1 (en) 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
ATE264340T1 (de) 1999-08-17 2004-04-15 Novo Nordisk Healthcare Ag Stabilisierung von gefriergetrocknetem kuchen
WO2001017542A1 (fr) 1999-09-08 2001-03-15 Chugai Seiyaku Kabushiki Kaisha Preparation de solution de proteines et procede de stabilisation associe
US6750053B1 (en) 1999-11-15 2004-06-15 I-Stat Corporation Apparatus and method for assaying coagulation in fluid samples
RU2278123C2 (ru) 2000-02-11 2006-06-20 Максиджен Холдингз Лтд. Молекулы, подобные фактору vii или viia
ES2449224T3 (es) * 2000-05-03 2014-03-18 Novo Nordisk Health Care Ag Administración subcutánea del Factor de coagulación VII
EP1282693B1 (en) 2000-05-03 2010-10-20 Novo Nordisk Health Care AG Human coagulation factor vii variants
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
PL365042A1 (en) * 2000-05-10 2004-12-27 Novo Nordisk A/S Pharmaceutical composition comprising a factor viia and a factor xiii
JP4361728B2 (ja) 2000-09-13 2009-11-11 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト凝固因子ｖｉｉ変異型
IL154880A0 (en) 2000-10-02 2003-10-31 Novo Nordisk As Method for the production of vitamin k-dependent proteins
AU2002218029A1 (en) 2000-11-09 2002-05-21 The Scripps Research Institute Modified factor viia
DE50114021D1 (de) 2001-01-08 2008-07-24 Csl Behring Gmbh Stabilisierte Flüssigzubereitung der den Blutgerinnungsfaktor VII aktivierenden Protease oder ihres Proenzyms
US6825323B2 (en) 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
KR101067400B1 (ko) 2001-07-10 2011-09-27 잇판자이단호진 가가쿠오요비겟세이료호겐쿠쇼 약제학적으로 안정한 지혈용 조성물
GB0117879D0 (en) 2001-07-21 2001-09-12 Common Services Agency Storage of liquid compositions
US6858587B2 (en) 2001-11-02 2005-02-22 Novo Nordisk Pharmaceuticals, Inc. Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
US20030119743A1 (en) 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors
US7125846B2 (en) 2001-11-09 2006-10-24 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
EP1446150A1 (en) 2001-11-09 2004-08-18 Novo Nordisk Health Care AG Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors
US7078479B2 (en) 2001-11-09 2006-07-18 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
CN1606452A (zh) 2001-12-21 2005-04-13 诺沃娜第克公司 修饰的因子ⅶ多肽的液体组合物
ES2325653T3 (es) 2001-12-21 2009-09-11 Novo Nordisk Health Care Ag Composicion liquida de polipeptidos del factor vii.
US20040009918A1 (en) 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
EP1503798B8 (en) 2002-05-03 2012-03-14 Novo Nordisk Health Care AG Stabilised solid compositions of modified factor vii
PT1517698E (pt) 2002-06-21 2014-11-19 Novo Nordisk Healthcare Ag Composições sólidas estabilizadas de polipéptidos do fator viia
US6933808B2 (en) 2002-07-17 2005-08-23 Qing Ma Microelectromechanical apparatus and methods for surface acoustic wave switching
EP1422309A1 (de) 2002-11-22 2004-05-26 Siemens Aktiengesellschaft Verwendung einer Sprühkompaktierungsanlage zur Erzeugung einer Schicht und Schichtsystem hergestellt mittels einer Sprühkompaktierungsanlage und Schichtsystem
AT501088A2 (de) 2002-12-18 2006-06-15 Bio Prod & Bio Eng Ag Stabile therapeutische proteine
WO2004082708A2 (en) 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
MXPA05012476A (es) 2003-05-23 2006-02-22 Novo Nordisk Healthcare Ag Estabilizacion de proteina en solucion.
JP2006527216A (ja) 2003-06-13 2006-11-30 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 新規調合物
CA2549593C (en) 2003-12-19 2014-02-11 Novo Nordisk Health Care Ag Stabilised compositions of factor vii polypeptides
CN101184474B (zh) 2005-04-28 2013-05-29 诺和诺德医疗保健公司 含有活化的凝血因子ⅶ多肽的密封容器，制备这种容器的方法，和试剂盒以及该试剂盒的使用方法

Also Published As

Publication number Publication date
WO2003055512A1 (en) 2003-07-10
US20120004176A1 (en) 2012-01-05
US8461116B2 (en) 2013-06-11
CA2470511A1 (en) 2003-07-10
US20040037893A1 (en) 2004-02-26
CN1607958A (zh) 2005-04-20
HUP0402315A2 (hu) 2005-02-28
AU2002351756A1 (en) 2003-07-15
HUP0402315A3 (en) 2009-03-30
IL162239A0 (en) 2005-11-20
ATE428439T1 (de) 2009-05-15
RU2357751C2 (ru) 2009-06-10
PL370652A1 (en) 2005-05-30
EP1458408B1 (en) 2009-04-15
US8022031B2 (en) 2011-09-20
CA2470511C (en) 2014-05-27
JP2005530683A (ja) 2005-10-13
DE60232017D1 (de) 2009-05-28
RU2004122398A (ru) 2005-03-20
EP1458408A1 (en) 2004-09-22
ES2325653T3 (es) 2009-09-11

Similar Documents

Publication Publication Date Title
BR0215216A (pt) Composição aquosa lìquida, método para preparar uma composição aquosa lìquida de um polipeptìdeo de fator vii, uso de uma composição aquosa lìquida, e, método para o tratamento de uma sìndrome de resposta ao fator vii
BR0215218A (pt) Composição aquosa lìquida, método para a preparação da mesma, uso de uma composição, e, métodos para a inibição da coagulação do sangue em um indivìduo, e inibição de reações mediadas pelo fator de tecido em um indivìduo
BR9906200A (pt) Emulsoes estaveis de substratos superbasicos gelificados com tensoativos e liquidos aguosos.
BRPI0413518A (pt) composição farmacêutica lìquida aquosa, método para preparar e uso da mesma, método para tratar uma sìndrome responsiva ao fator vii, e, recipiente hermético
BR0207420A (pt) Processo e composições para desinfecção de superfìcies duras
ATE547114T1 (de) Flüssige zusammensetzungen von factor vii polypeptiden
BRPI0417721A (pt) kit contendo um medicamento farmacêutico, métodos para preparar uma formulação lìquida de um polipeptìdeo de fator de coagulação sangüìnea e para tratar uma sìndrome responsiva a fator de coagulação, uso de um polipeptìdeo de fator vii, composição, e, métodos para preparar as composições e para tratar uma sìndrome responsiva a fvii
PE84799A1 (es) Metodos mejorados para el procesamiento de proteina c activada
PT1100344E (pt) Novas composicoes liquidas contendo quitosana e metodos para a sua preparacao e utilizacao
KR880004819A (ko) 펩티드 제제
KR900015722A (ko) N-(3,4-디메톡시신나모일) 안트라닐산을 함유하는 약제 조성물
BRPI0408439A (pt) composição farmacêutica lìquida aquosa, método para preparar e uso da mesma, método para tratar uma sìndrome responsiva ao fator vii, e, recipiente hermético
BR9809310A (pt) Composição lìquida aquosa derramável, composições farmacêuticas e processos para o tratamento da esofagite de refluxo, gastrite, dispepsia ou ulceração péptica, e para formar um revestimento protetor sobre o tecido da mucosa gastrintestinal, composição farmacêutica em forma de dosagem unitária sólida.
BRPI0414262A (pt) método de tratamento de um sistema aquoso contendo ou em contato com incrustação de sulfeto de metal, mistura sinérgica, formulação, e, uso da mistura sinérgica
KR940005498A (ko) 인공 해수
ATE505555T1 (de) Fusionsproteine zur insektenbekämpfung
ATE268590T1 (de) Pharmazeutische emulsion enthaltend sorbinsäure, na-edta und borsäure
DE60239329D1 (de) Verwendung von lanthankarbonat zur prävention von nierensteinleiden
DE69221153D1 (de) Kationselektive Elektroden
DE69940051D1 (de) Wasserlösliche trockene zusammensetzungen
BR9911372A (pt) Preparações pesticidas sob a forma de suspensão aquosa
KR920018076A (ko) 신규 폴리펩티드
ZA814523B (en) Salt of furosemide or piretanide as the acid component and penbutolol or (-).3-(4)-(3-(3,4-dimethoxyphenylethylamino)-2-hydroxy-proposy)-phenyl)crotononitrile as the base component,process for its prepration,composition in which it is present and its use
Kim et al. Regulation of acetylcholine esterase and neurotransmitters in Oryzias latipes by diazinon
ATE290387T1 (de) Ribavirin-granulat zur herstellung von filmtabletten

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: NOVO NORDISK HEALTH CARE AG (CH)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]